Aarey Drugs & Pharmaceuticals Ltd. (IN:AAREYDRUGS)
:AAREYDRUGS
Top Page
Aarey Drugs & Pharmaceuticals Ltd.
(AAREYDRUGS)
Select Model
Select Model
Rating:50Neutral
Price Target:
₹69.00
▲(1.43% Upside)
Action:ReiteratedDate:04/11/26
The score is held back primarily by weak profitability and pressured cash flows, despite a relatively stable balance sheet. Technical indicators are broadly neutral with a negative MACD and price below longer-term moving averages. Valuation further weighs on the score due to a very high P/E and no dividend yield provided.
Positive Factors
Balance sheet strength
A low D/E (0.25) and a high equity ratio (58.09%) provide durable financial flexibility. This reduces refinancing and solvency risk, supports funding for working capital or targeted investment, and gives the company resilience through industry cycles over the next several months.
Negative Factors
Very weak profitability
Extremely low gross and net margins constrain the company's ability to reinvest, fund R&D, or absorb cost shocks. Persistently weak margins also limit return on equity and reduce the scope for long-term competitive reinvestment without structural margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A low D/E (0.25) and a high equity ratio (58.09%) provide durable financial flexibility. This reduces refinancing and solvency risk, supports funding for working capital or targeted investment, and gives the company resilience through industry cycles over the next several months.
Read all positive factors
Aarey Drugs & Pharmaceuticals Ltd. (AAREYDRUGS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.86B
Dividend YieldN/A
Average Volume (3M)7.61K
Price to Earnings (P/E)84.5
Beta (1Y)1.46
Revenue Growth-17.47%
EPS Growth-50.07%
CountryIN
Employees132
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.20
Shares Outstanding28,354,303
10 Day Avg. Volume5,578
30 Day Avg. Volume7,610
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)0.75
Price to Sales (P/S)0.22
P/FCF Ratio-23.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aarey Drugs & Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, bulk drugs, intermediates, and specialty chemicals for various industrial applications in India. The company provides mono methyl and die methyl urea, ...
How the Company Makes Money
null...
Aarey Drugs & Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
60
Neutral
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.28B | 4.74B | 3.95B | 4.19B | 4.92B | 3.48B |
| Gross Profit | 106.49M | 91.32M | 132.04M | 115.07M | 195.45M | 100.98M |
| EBITDA | 122.55M | 120.64M | 114.16M | 104.50M | 140.63M | 116.65M |
| Net Income | 35.83M | 40.24M | 46.84M | 37.71M | 65.55M | 65.14M |
Balance Sheet | ||||||
| Total Assets | 2.94B | 2.38B | 3.03B | 2.91B | 2.45B | 2.33B |
| Cash, Cash Equivalents and Short-Term Investments | 81.90M | 32.29M | 28.90M | 11.24M | 1.92M | 6.50M |
| Total Debt | 507.79M | 348.56M | 313.52M | 377.18M | 141.62M | 180.17M |
| Total Liabilities | 1.45B | 997.86M | 1.71B | 1.74B | 1.32B | 1.34B |
| Stockholders Equity | 1.49B | 1.38B | 1.33B | 1.17B | 1.14B | 988.60M |
Cash Flow | ||||||
| Free Cash Flow | 45.49M | -43.10M | -37.16M | -23.25M | -66.94M | 25.98M |
| Operating Cash Flow | 145.98M | 8.95M | -29.94M | -12.81M | -44.93M | 54.77M |
| Investing Cash Flow | -100.49M | -59.39M | -17.02M | 4.41M | -21.97M | -28.79M |
| Financing Cash Flow | 11.69M | 49.24M | 55.85M | 13.54M | 22.53M | -24.51M |
Aarey Drugs & Pharmaceuticals Ltd. Technical Analysis
Neutral
68.03
Price Trends
67.16
Negative
71.17
Negative
72.40
Negative
Market Momentum
-2.54
Negative
52.61
Neutral
77.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AAREYDRUGS, the sentiment is Neutral. The current price of 68.03 is above the 20-day moving average (MA) of 62.84, above the 50-day MA of 67.16, and below the 200-day MA of 72.40, indicating a neutral trend. The MACD of -2.54 indicates Negative momentum. The RSI at 52.61 is Neutral, neither overbought nor oversold. The STOCH value of 77.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AAREYDRUGS.
Aarey Drugs & Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹3.43B | 48.53 | ― | ― | -0.77% | 2055.99% | |
64 Neutral | ₹1.46B | 21.48 | ― | ― | 14.53% | -10.49% | |
58 Neutral | ₹1.20B | 16.40 | ― | 1.62% | -9.07% | 5.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ₹1.86B | 84.53 | ― | ― | -17.47% | -50.07% | |
45 Neutral | ₹1.27B | -11.90 | ― | ― | -46.31% | -26.28% |
* Healthcare Sector Average
IN:AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd.
68.65
18.25
36.21%
IN:ALPA
Alpa Laboratories Limited
69.53
-35.77
-33.97%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
145.00
70.10
93.59%
IN:BALPHARMA
Bal Pharma Limited
75.32
-29.30
-28.01%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
58.97
-14.81
-20.07%
IN:NATCAPSUQ
Natural Capsules Limited
153.60
-58.40
-27.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.